2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
May 3rd 2022
Lori A. Leslie, MD, reviews how the approval of axicabtagene ciloleucel may impact or enhance current practice patterns for adult patients with large B-cell lymphoma.
April 19th 2022
Marlana M. Orloff, MD, overviews how pivotal efficacy and safety data of tebentafusp will improve the treatment paradigm for adult patients with HLA-A*02:01–positive unresectable or metastatic uveal melanoma.
April 11th 2022
Perioperative pembrolizumab plus standard of care chemotherapy followed by adjuvant pembrolizumab showed a meaningful pathological complete response rate in patients with resectable gastric and gastroesophageal junction adenocarcinoma.
April 11th 2022
In the ENDOLA trial, olaparib in combination with metronomic cyclophosphamide and metformin showed a significant non-progression rate in patients with recurrent advanced or metastatic endometrial cancer.
April 5th 2022
Patients who develop post–essential thrombocythemia myelofibrosis or post–polycythemia vera myelofibrosis, which are associated with significant symptom burden and bone marrow failure, have limited therapies available for effective treatment.
April 4th 2022
“I can’t conceive of anything worse than being in a situation where you can’t ask, ‘How do we get better?’ ”
April 1st 2022
Distinctions in histology, molecular profiles, and tumor location have set diverging course of care for the treatment of patients with gastrointestinal cancers.
March 18th 2022
The durable antitumor activity of pembrolizumab and the clinically beneficial outcomes demonstrated with both adjuvant chemotherapy and adjuvant chemoradiotherapy have provided investigators with the foundation to assess the 2 approaches in combination in a phase 3 study.
March 15th 2022
Effective treatment paths leveraging neoadjuvant chemotherapy have been well-established for patients with muscle-invasive bladder cancer, with mounting retrospective and prospective data continuing to demonstrate overall survival benefit compared with adjuvant chemotherapy.
March 10th 2022
Since most diagnoses of esophageal squamous cell carcinoma are made when the disease is in advanced stages, investigators have initiated studies to evaluate the efficacy of immunotherapy in earlier lines of therapy, including in combination with chemoradiotherapy.
March 4th 2022
Charles L. Loprinzi, MD, discusses some of the most common treatment-related toxicities in breast cancer and provided insight into various current and investigational approaches available to patients.
February 19th 2022
At a nearly 3-year median follow-up, health-related quality-of-life scores were improved or maintained over time among patients with advanced renal cell carcinoma who received with nivolumab plus cabozantinib compared with those who received sunitinib.
February 4th 2022
In 2021, 13 novel agents were approved across hematology/oncology. Additionally, there were many other notable approvals—whether they were new formulations, expanded indications, or biosimilar approvals—across tumor types that expanded accessibility for varying patient populations.
January 24th 2022
Ajai Chari, MD, reviews the takeaways from the PLEIADES trial and its comparability with the CANDOR trial, and how a subcutaneous formulation of a daratumumab combination became a pivotal player in the treatment enhancement for patients with relapsed or refractory multiple myeloma.
January 14th 2022
Jeffrey S. Weber, MD, PhD, overviews the successes made in the melanoma setting in the past decade and the challenges to overcome in the future.
December 17th 2021
Pembrolizumab demonstrated a statistically significant and clinically meaningful improvement in disease-free survival vs placebo as a postnephrectomy adjuvant therapy in patients with renal cell carcinoma at intermediate-high or high risk of recurrence, and in those who are M1 with no evidence of disease.
November 20th 2021
Joel Neal, MD, PhD, discusses the evolving treatment landscape for patients with EGFR exon 20–mutant non–small cell lung cancer.
November 8th 2021
The addition of immune checkpoint inhibitors and targeted therapies has paved the way for advances in the adjuvant and met-astatic setting with recent data from clinical trials demonstrating significant improvements in overall survival for patients with advanced melanoma.
October 19th 2021
Hope S. Rugo, MD, FASCO, provides her insights on the final analysis data from the international phase 3 ASCENT trial.
September 19th 2021
Lisocabtagene maraleucel in combination with ibrutinib was associated with manageable safety for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, according to updated data from the phase 1 TRANSCEND-CLL-004 trial.